Prenosis
Founded 2014 · 44 employees on LinkedIn · 1 known investors
Prenosis develops AI-powered precision medicine diagnostics for acute care, built on its Immunix platform and a biobank of clinical data for infection. Its Sepsis ImmunoScore is an FDA-authorized AI diagnostic that integrates biomarkers and clinical data into hospital electronic medical records to diagnose sepsis and predict patient outcomes.
Investors · 1
Non-dilutive funding · 6 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1.3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1.2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2M |
| National Science Foundation | Phase II | 2018 | $704.5K |
| National Science Foundation | Phase I | 2017 | $150K |
| Centers for Disease Control and Prevention (CDC)Centers for Disease Control and Prevention | Phase I | 2017 | $150K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Prenosis do?
- Prenosis develops AI-powered precision medicine diagnostics for acute care, built on its Immunix platform and a biobank of clinical data for infection. Its Sepsis ImmunoScore is an FDA-authorized AI diagnostic that integrates biomarkers and clinical data into hospital electronic medical records to diagnose sepsis and predict patient outcomes.
- Who are Prenosis's investors?
- Prenosis's investors include PACE Healthcare Capital.